1287745-32-7

Downstream Products

• 1352621-98-7 (R)-N-((R)-1-((3S,4S)-4-(4-chlorophenyl)-3,4-dihydroxy-3-methylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-3,3-difluorocyclopentanecarboxamide 
• 1352621-96-5 (R)-3,3-difluorocyclopentanecarboxylic acid 
• 1352621-94-3 (R)-benzyl 3,3-difluorocyclopentanecarboxylate 
• 1287746-31-9 (5R,7R)-N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-1-methyl-2,4-dioxo-1,3-diazaspiro[4.4]nonane-7-carboxamide 
• 1287746-33-1 (5S,7R)-N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-1-methyl-2,4-dioxo-1,3-diazaspiro[4.4]nonane-7-carboxamide 
• 1287746-06-8 (2R,5R)-N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-7-oxo-6-oxa-8-azaspiro[4.5]decane-2-carboxamide 
• 1287746-08-0 (2R,5S)-N-((R)-1-((S)-4-(4-chlorophenyl)-4-hydroxy-3,3-dimethylpiperidin-1-yl)-3-methyl-1-oxobutan-2-yl)-7-oxo-6-oxa-8-azaspiro[4.5]decane-2-carboxamide 
• 1287746-01-3 (2R)-benzyl 7-oxo-6-oxa-8-azaspiro[4.5]decane-2-carboxylate 
• 1287745-96-3 (1R)-benzyl 3-hydroxy-3-(2-oxoethyl)cyclopentanecarboxylate 
• 1287745-77-0 2-((3R)-3-(benzyloxycarbonyl)-1-hydroxycyclopentyl)acetic acid 
• 1287745-37-2 (1R)-benzyl 3-(tert-butoxycarbonylamino)-3-(2-oxoethyl)cyclopentanecarboxylate 
• 1287745-35-0 (1R)-benzyl 3-allyl-3-(tert-butoxycarbonylamino)-cyclopentanecarboxylate 

Relevant academic research and scientific papers

Tetrahydroquinazolinone Derivatives as PARP Inhibitors

Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, R7a-d, R8a-d, A, M, n, and p are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.

TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS

Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, R7a-d, R8a-d, A, M, n, and p are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.